Ketamine Therapy in Mississippi

Mississippi follows federal regulatory frameworks governing the clinical use of ketamine, which remains a Schedule III controlled substance under the Controlled Substances Act. Ketamine clinics operating in Mississippi must comply with regulations established by the Mississippi State Board of Medical Licensure (MSBML), which oversees physician licensing and the standards of care required for administering controlled substances. Providers must hold an active and unrestricted medical license in the state, along with a valid DEA registration that authorizes them to prescribe and administer Schedule III substances. Facilities are also subject to inspection and compliance requirements related to controlled substance storage, documentation, and dispensing practices.

In Mississippi, ketamine is legally administered in clinical settings primarily as an off-label treatment for conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD), chronic pain, and certain anxiety disorders. The off-label use of FDA-approved medications is a well-established and legal practice in American medicine, and physicians in Mississippi retain the professional discretion to recommend ketamine infusions when clinically appropriate. However, the newer nasal spray formulation esketamine (Spravato), which is FDA-approved specifically for treatment-resistant depression, must be administered under a certified Risk Evaluation and Mitigation Strategy (REMS) program, requiring patients to be monitored on-site for at least two hours following each administration.

Ketamine clinics in Mississippi are generally expected to adhere to the following operational and regulatory standards:

• All administering physicians must maintain current licensure with the MSBML and a valid DEA registration
• Facilities must comply with Mississippi state laws governing controlled substance record-keeping and storage security
• Clinics offering Spravato must be enrolled in and compliant with the FDA's REMS certification program
• Patient informed consent must be properly documented prior to initiating treatment
• Clinics must maintain appropriate emergency protocols and equipment for monitoring patients during infusions

Prospective patients seeking ketamine therapy in Mississippi should ensure that any clinic they consider is fully licensed and transparent about its clinical protocols and provider credentials. Because most insurance plans do not cover ketamine infusions for mental health indications, patients are typically responsible for out-of-pocket costs, though Spravato coverage through insurance is more common. The regulatory landscape surrounding ketamine therapy continues to evolve at both the state and federal levels, and patients are encouraged to consult directly with providers and refer to the Mississippi State Board of Medical Licensure for the most current guidance.